Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece
Open Access
Abstract
The aim of our study was to assess the immunogenicity of the third dose of the BNT162b2 mRNA COVID-19 vaccine (Comirnaty) in a cohort of 129 health-care workers in Greece whose anti-S1 RBD IgG titers were monitored over the course of nine months. Titers were measured for each participant just before the third dose (nine months after the second dose) and also one month after the third dose. Of the 129 participants, 19 had been previously infected before starting the vaccination scheme. The SARS-CoV-2 IgG II Quant assay on the Architect System was employed to longitudinally assess the titers of IgG against the receptor-binding domain of the S1 subunit of the spike protein (anti-S1 RBD). Boosters raised Geometric Mean Concentrations (GMCs) by a factor of approximately 47 relative to levels at 9 months and by a factor of approximately 23 relative to levels at 6 months. The immune response one month after the third dose was significantly higher than the response achieved one month after the second dose (p = 0.008). In conclusion, our findings verify the potent immunogenicity elicited by the third dose in all age and prior COVID-19 status groups, suggesting that the timely administration of the third (booster) dose maximizes the immunogenic potential of the vaccine.Keywords
Funding Information
- Greek pharmaceutical company GAP S.A. (ELKE AUTH 72792)
This publication has 25 references indexed in Scilit:
- Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysisKidney International, 2021
- Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 VaccinemedRxiv, 2021
- Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workersJournal of Medical Microbiology, 2021
- Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositiveVaccine, 2021
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19New England Journal of Medicine, 2021
- Impact of vaccination on new SARS-CoV-2 infections in the United KingdomNature Medicine, 2021
- Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine BoostermedRxiv, 2021
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataThe Lancet, 2021
- Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccineAmerican Journal of Hematology, 2021
- Dilution Protocols for Detection of Hook Effects/Prozone PhenomenonClinical Chemistry, 2000